360 results about "Pharmaceutical industry" patented technology

The invention discloses fermented lactobacillus mucus NJ-10 and application thereof in preparation of rare ginsenoside-rich metagen through fermentation conversion, and relates to the field of probiotic fermentation. The lactobacillus fermentum NJ-10 is preserved in the China Center for Type Culture Collection on February 25, 2025, and the preservation number of the lactobacillus fermentum NJ-10 is CCTCC (China Center for Type Culture Collection) NO: M 2025300. According to the present invention, the fermentation lactobacillus mucus NJ-10 capable of producing beta-glucosidase, which is subjected to autonomous separation and identification, can be used for fermentation and conversion of ginseng stem and leaf saponin, and then is subjected to post-generation preparation in a high-temperature and high-pressure steam manner, such that the beta-glucosidase producing beta-glucosidase can be produced, and the beta-glucosidase producing beta-glucosidase producing beta-glucosidase producing beta-glucosidase producing beta-glucosidase producing beta-glucosidase can be produced. According to the method, ginseng stem and leaf saponin is converted through two-step fermentation to prepare the postbiotic fermentation product rich in rare ginsenoside, resource utilization of non-medicinal parts of ginseng is expanded, and the postbiotic fermentation product has wide application prospects in the fields of food industry, pharmaceutical industry, cosmetics, animal breeding and the like.

The invention discloses a drug production safety robot inspection method, which comprises the following steps: acquiring multi-source heterogeneous data of a drug production safety state in real time, including environment sensor data, intelligent video data and equipment operation parameters; based on the multi-source heterogeneous data, constructing and dynamically updating a production safety risk assessment model; according to the production safety risk assessment model, a self-adaptive inspection task is generated and adjusted, and the task defines an inspection target, a path, a period and an execution maneuvering terminal; scheduling the maneuvering terminal to execute the inspection task, driving the multi-mode AI potential safety hazard identification engine by the returned safety state data and outputting an identification result; and an identification result is fed back to the production safety risk assessment model to form closed-loop control. The invention also discloses an intelligent inspection system for pharmaceutical production safety. According to the invention, prospective risk early warning, self-adaptive task scheduling and closed-loop self-optimization can be realized, so that higher requirements of the modern pharmaceutical industry on personnel safety, public health and compliance production can be met.

The invention relates to a big data analysis technology-based process impurity and degraded impurity relationship analysis method, which comprises the following steps of: calculating correlation coefficients among process impurities, typical impurity variables and degraded impurities through a canonical correlation analysis method; and constructing a transfer relationship among various impurities, typical impurity variables and various degraded impurities through correlation coefficient screening, so as to judge the correlation degree between the process impurities and the degraded impurities. The analysis method provided by the invention comprehensively analyzes the impurity formation rule of the medicine in the production, storage and use processes, deeply excavates the correlation between process impurities and degraded impurities, reveals the internal relevance of different impurities, not only helps to guide the direction of impurity spectrum research, but also helps to improve the quality of the medicine. Scientific basis is provided for control of key impurities of drugs and process optimization, the safety and effectiveness of the drugs are improved, and further development of pharmaceutical science and pharmaceutical industry is promoted.

The invention discloses a whole pharmaceutical factory complex working condition waste gas comprehensive treatment control system, which relates to the technical field of pharmaceutical industry waste gas treatment, and comprises a low-concentration waste gas treatment system, a high-concentration waste gas treatment system, a fuel pretreatment and conveying system, a heat recovery system and a control system of each flow. Waste gas of the low-concentration waste gas treatment system and waste gas of the high-concentration waste gas treatment system come from a plurality of workshops, and the low-concentration waste gas treatment system conducts concentration treatment to obtain high-concentration waste gas which is then conveyed to the high-concentration waste gas treatment system to be treated. The fuel pretreatment and conveying system is responsible for providing fuel meeting the requirement for the high-concentration waste gas treatment system, waste gas is treated by the high-concentration waste gas treatment system, then exhaust gas is subjected to heat recovery through the heat recovery system, and the exhaust gas is used for preheating sewage of the sewage treatment system, analyzing a rotating wheel and the like. Through cooperation of all processing systems, stable, safe, continuous and efficient operation of the system is ensured.

The invention provides a specific sequence nucleic acid molecule and application thereof as a PDRN, and relates to the technical field of biology. A novel nucleic acid molecule with a specific sequence is obtained, and the sequence has certainty, biological activity and stable product quality. The PDRN of the specific sequence does not have cytotoxicity, is high in safety and has a wide application prospect. Moreover, compared with the extracted PDRN, the PDRN with a specific sequence is found for the first time, the product has a remarkable effect of promoting VEGF expression, cell damage can be effectively repaired, and a novel skin-care and repairing functional component is provided for the industries of cosmetics and medicines. The invention further provides a preparation method of the PDRN with the specific sequence, and the preparation method is simple and suitable for popularization, application and industrial production.

The invention discloses a preparation method of a dehydroabietic acid cellulose ester (DCE) bonded silica gel stationary phase, which comprises the following steps: firstly, carboxylating the surface of a SiO2 microsphere with a core-shell structure, then carrying out acylating chlorination, and then preparing amphiphilic DCE coated SiO2 solid particles with DCE in a chemical bonding manner. The DCE-SiO2 solid particle has the pore diameter of 5-30nm and the specific surface area of 50-400m < 2 > / g, has the characteristics of intact particle shape, uniform particle size, high mechanical strength, high pressure resistance and the like, and can be used as a liquid chromatographic column filler. The preparation method is simple and convenient, the column pressure is low, the repeatability is good, the chemically modified DCE has a phenanthrene ring skeleton and has good selective separation performance on saponin drugs containing ring structures, and the application prospect in the pharmaceutical industry is wide.

The invention provides a method for detecting the content of liquiritin and glycyrrhizic acid in liquorice decoction pieces based on hyperspectrum, and relates to a method for rapidly and nondestructively predicting the content of index components of the liquorice decoction pieces by using a hyperspectrum technology. The method comprises the following implementation steps: acquiring a hyperspectral image of the liquorice decoction piece, determining the liquid phase content of the liquorice decoction piece, preprocessing the hyperspectral image, establishing a content prediction model, and quickly and nondestructively detecting the liquorice decoction piece. The method comprises the following steps: collecting licorice decoction pieces in a short-wave infrared band by using a hyperspectral imaging technology, determining the contents of liquiritin and glycyrrhizic acid in a collected sample through liquid chromatography, extracting characteristic wavelengths according to the content measurement data, comparing the advantages and disadvantages of different characteristic variable extraction methods and content prediction models, and determining the content of glycyrrhizic acid in the licorice decoction pieces. Therefore, rapid nondestructive detection of the liquiritin and glycyrrhizic acid content in the licorice decoction pieces is realized, an analysis method is provided for rapid grading and screening of the traditional Chinese medicine decoction pieces, digitization, intelligence and greenization of the traditional Chinese medicine industry are promoted, and improvement of the equipment manufacturing level of the pharmaceutical industry is promoted.

The swing arm type rubber plug cleaning machine comprises a machine body, a cleaning tank is arranged in the machine body, a partition plate is arranged in the cleaning tank, an overflow hole is formed in the partition plate, an overflow tank is formed in the cleaning tank through the partition plate, and an overflow water outlet is formed in the side face of the overflow tank. A lifting mechanism is arranged in one side of the machine body and comprises a fixing column. The rubber plug cleaning process comprises the stages of cleaning water overflow cleaning, ultrasonic overflow cleaning and bubbling overflow cleaning, different cleaning modes and time are set in each stage according to different formulas, the cleaning modes and time can be recorded and reports can be formed, residues of fine structures such as rubber plug navel holes and pores can be effectively removed through the multiple cleaning modes, and the cleaning efficiency is improved. The cleanliness reaches the sterile production standard in the pharmaceutical industry; automatic equipment reduces the risk of secondary pollution caused by manual sequence transfer, and conforms to the GMP specification; the equipment can be adapted to rubber plugs with different specifications, and the rubber plugs are not easy to damage.

The invention discloses a pollution source dynamic acquisition and monitoring method and system, relates to the technical field of pollution source dynamic acquisition and monitoring, and solves the problem that a scheme capable of sensing the pollution situation and autonomously optimizing the monitoring frequency is difficult to set in pharmaceutical production. And a dynamic threshold is difficult to set according to the dynamic influence of the environmental variable on the pollution diffusion rule. According to the method, the predicted pollution concentration of the current time period is obtained through the pre-evaluation model; determining the data acquisition frequency of the current time period according to the pollution concentration of the previous time period and the predicted pollution concentration of the current time period; acquiring the pollution concentration of each pollution source in the current time period based on the data acquisition frequency of the current time period; determining an alarm instruction of each pollution source based on the pollution concentration in the current time period, and giving an alarm based on the alarm instruction; according to the invention, environmental risk control can be changed from passive response to active prevention, and technical support is provided for green production and sustainable development of the pharmaceutical industry.

The invention discloses a method for detecting related substances in imaric acid dihydrochloride by HPLC (High Performance Liquid Chromatography), and belongs to the technical field of chemical engineering and pharmacy, the related substances in the imaric acid dihydrochloride are detected by high performance liquid chromatography, a phosphate buffer solution (0.05 mol / L of monopotassium phosphate solution, and pH adjusted to 2.5 by phosphoric acid) is used as a mobile phase A, acetonitrile is used as a mobile phase B, gradient elution is carried out, the flow rate is 1.0 ml / min, the detection wavelength is 250nm, and the detection wavelength is 250nm. The column temperature is 40 DEG C, and the detection wavelength is 235nm; the method can be used for effectively separating and quantitatively detecting imatamide, demethylated imaric acid dihydrochloride, ortho-imaric acid, meta-imaric acid, p-hydroxymethyl benzamide, an intermediate B, p-hydroxymethyl benzoic acid, an imaric acid dimer, p-cyanobenzyl alcohol, p-chloromethyl benzamide, p-toluic acid and p-chloromethyl benzoic acid in the imaric acid dihydrochloride. The method disclosed by the invention is simple and convenient to operate, strong in specificity, high in sensitivity and accuracy, good in linearity and capable of effectively controlling the quality of a p-imaric acid dihydrochloride product.

The invention discloses a compound residue detection method, which adopts liquid chromatography (HPLC) to perform quantitative analysis on residual vomitinib on the surface of equipment, can quickly and accurately determine the drug residue, and ensures that the production environment is clean and meets the drug production quality standard. The method comprises the following steps: preparing a solution, collecting a sample by using a wiping method or a leaching method, and preparing a diluent, a reference stock solution, a reference substance solution and a test solution. The chromatographic conditions are that a Thermo C18 chromatographic column is adopted, the detection wavelength is 332 nm, a mobile phase A is a phosphate buffer solution, a mobile phase B is acetonitrile, and the flow velocity is 1.0 ml / min. Through the method, the residual quantity of the vomitinib can be efficiently detected, the thorough cleaning of production equipment is ensured, the cross contamination of medicines is avoided, and the quality control level of the medicines is improved. The method has the advantages of simplicity and convenience in operation, rapidness in detection, high sensitivity and the like, and is widely applicable to detection and control of drug residues in the pharmaceutical industry.

The invention belongs to the technical field of plant tissue culture, and particularly relates to an induction method of adventitious roots of cinnamomum camphora. According to the method disclosed by the invention, the adventitious root induction rate of the adventitious root of the cinnamomum camphora is remarkably improved by establishing a sterile system of the cinnamomum camphora, culturing cluster buds and sterile seedlings, promoting rooting of tissue culture seedlings, inhibiting browning, enabling the adventitious buds to extend and inducing the adventitious root through three ways, so that the problems of shortage of borneol resources and high market demand are solved; the method for inducing the adventitious roots of the cinnamomum camphora can be used for industrial production, and sufficient raw materials are provided for extraction of borneol; according to the method, large-scale culture of the adventitious roots of the cinnamomum camphora is achieved, a large number of pharmaceutical raw materials can be obtained at low cost in a short time, and an integrated production system can be formed with the pharmaceutical industry. The technology has important practical significance for promoting the development of the cinnamomum camphora industry, expanding the application of the pharmaceutical field, constructing a rare and endangered traditional Chinese medicinal material breeding technology system and realizing sustainable development and utilization.

The invention relates to a pharmaceutical composition in the form of orodispersible powder comprising simeticone and alverine citrate, as well as to the method for manufacturing same; to a pharmaceutical composition in dry form containing simeticone and to the method for manufacturing same; and to a pharmaceutical composition in the form of grains comprising alverine citrate and to the method for manufacturing same. The pharmaceutical composition comprising a mixture of alverine citrate and simeticone according to the invention comprises grains composed of simeticone adsorbed onto a powdered solid support, granules containing grains containing alverine citrate, wherein the outer surface of these grains is coated with a film made of a masking agent, and pharmaceutically acceptable excipients comprising at least one flavouring, and / or at least one acidifier, and / or at least one sweetener, and / or at least one lubricating / anti-aggregating agent, and / or at least one filler. The invention is intended for use in the pharmaceutical industry.

The invention relates to a method for producing fermented vegetable oil by a semi-continuous fed-batch fermentation process, which comprises the following steps: firstly, inoculating a strain into a fermentation culture medium for thallus propagation under proper conditions, then mixing with crude vegetable oil according to a certain proportion, fermenting at proper temperature, and discharging part of fermentation liquor after the fermentation index reaches a set value, thereby obtaining the fermented vegetable oil. And returning a water phase containing active thalli to the fermentation tank, and meanwhile, supplementing fresh vegetable oil crude oil with the same mass as the water phase to continue fermentation. And repeating the steps until the time of the acid value of the oil phase of the fermentation liquid reaching the set value exceeds 24 hours or is more than two times of the time of the fermentation reaching the set value after the previous oil supplement, ending the fermentation, and centrifugally separating and purifying the separated oil phase to obtain the fermented vegetable oil. The production efficiency of the fermented vegetable oil can be greatly improved, the single-batch production yield is improved, the stability of the quality of the fermented oil is ensured, the production cost is saved, and the method can be widely applied to the cosmetic and skin care field, the food field or the pharmaceutical industry.

In the pharmaceutical industry, a swinging tablet counting machine is usually used for filling tablets, but the situation that a plurality of tablets are stacked in one tablet counting hole occurs, so that filling difference is caused. The utility model discloses an improved swing tablet counting machine assembly which comprises a tablet counting disc, a discharging disc, a rotating transmission shaft, a power source, a material guiding pipe, a brush and a positioning clamp assembly. The swing tablet counting machine is improved on the basis of a traditional swing tablet counting machine, the position of the brush can be controlled by adjusting the relative position relation of the positioning clamp assemblies, the area of a tablet charging area can be adjusted, meanwhile, redundant tablets can be automatically removed, and therefore the defect that multiple tablets are stacked in one tablet counting hole of the traditional swing tablet counting machine is overcome. The brush and the positioning clamp assembly can be separated from each other, and the device can be suitable for material protection cylinders with different heights, and is simple to overhaul and replace and low in cost.

This invention discloses a highly efficient asymmetric synthesis method for aryl propionic acid drug molecules. The method uses racemic aldehydes as substrates and thiamine pyrophosphate-dependent enzymes as biocatalysts. Electrolysis is performed in a diaphragm-free electrolytic cell under conditions of an external redox dielectric and constant current, in a buffer salt solution and nitrogen atmosphere. This method achieves dynamic kinetic oxidation of aldehydes via bioelectrocatalysis, enabling the high-efficiency and high enantioselectivity synthesis of aryl propionic acid drug molecules. The method eliminates the need for redox agents and additives, is simple to operate, operates under mild reaction conditions, and is green and sustainable. This invention applies bioelectrocatalysis to asymmetric synthesis, providing a green and efficient new enzymatic synthetic route for the asymmetric synthesis of aryl propionic acid drug molecules, which has significant application prospects in the pharmaceutical industry.

1. The name of the product under this design: Magnetic Stirrer (Multi-heating MSM‑H). 2. Purpose of this product design: This product design is an experimental instrument with multiple magnetic stirring stations that can simultaneously stir and mix multiple groups of samples at the same speed. It is used in the petroleum, chemical, biological and pharmaceutical industries. 3. The key point of the design of this product lies in its shape. 4. The picture or photo that best illustrates the design points: three-dimensional picture.

The utility model discloses an anti-blocking filling machine for capsule medicine preparation and belongs to the technical field of medicine production. A medicine inlet is formed in the upper end of the shell, a stirring mechanism is arranged in the shell and fixedly connected with an anti-blocking mechanism, the anti-blocking mechanism is arranged in a conveying pipe, the conveying pipe is fixedly communicated with the upper end of the shell, a discharging port is formed in the lower end of the conveying pipe, an electronic valve is arranged on the discharging port, and the outer wall of the lower end of the conveying pipe is fixedly connected with a connecting frame. The connecting frame is fixedly connected with the fixing plate, the fixing plate is provided with a filling mechanism, and the filling mechanism corresponds to the discharging port. By means of the unique design and working principle, the capsule medicine preparation device has the remarkable advantages of being efficient in stirring, excellent in anti-blocking performance, accurate in filling, easy and convenient to operate, wide in application and the like, and efficient, reliable and automatic capsule medicine preparation equipment is provided for the pharmaceutical industry.

This invention provides specific sequence nucleic acid molecules and their applications as PDRNs, relating to the field of biotechnology. This invention yields novel specific sequence nucleic acid molecules with deterministic sequences, stable biological activity, and stable product quality. The PDRNs with these specific sequences are non-cytotoxic, exhibit high safety, and have broad application prospects. Furthermore, this invention is the first to discover that specific sequence PDRNs, compared to extracted PDRNs, significantly promote VEGF expression and effectively repair cell damage, providing a novel skincare and repair ingredient for the cosmetics and pharmaceutical industries. This invention also provides a simple method for preparing specific sequence PDRNs, suitable for widespread application and industrial production.

The utility model provides a western medicine double -layer tablet production is with double hopper precision filling structure, belongs to production technical field, including first workstation, the surface of first workstation is installed with filling structure, and filling structure is used for filling to double -layer tablet, filling structure includes hopper, hopper fixedly arranged in the surface of first workstation, hopper sets up two, two hoppers are provided with the discharge gate, through the setting of filling structure, the transmission design of servo motor plus different number of teeth driven gear, through the transmission ratio of adjusting gear and pulley, can control the rotating speed of two hoppers inner impeller respectively, combine the accurate calculation of volume of impeller upper feed inlet, can realize independent, accurate quantitative feeding according to the filling amount demand (such as the upper layer and lower layer weight ratio of double -layer tablet) of two raw materials, makes two layers raw material weight deviation control in very small range, accords with the strict standard of tablet weight difference of pharmaceutical industry, ensures the medicine dose accurate.

This invention belongs to the field of pharmaceutical drying technology and discloses a pharmaceutical drying and automatic lifting mixing device based on negative pressure fluidization, including a machine body, a lifting cylinder, and a second waste gas guide channel. In use, the invention drives the spiral lifting blades through a waste gas power transmission component, achieving automatic lifting and discharge of the dried material. This eliminates the need for manual transfer, reducing operator workload, improving production efficiency, and avoiding material contamination during transfer, thus meeting the clean production requirements of the pharmaceutical industry. Simultaneously, the pneumatic reciprocating lifting component drives the periodic lifting and lowering of the material plate, continuously agitating the material during the drying process. This breaks the limitations of static drying in existing equipment, ensuring that the material is uniformly exposed to hot air from all directions. This avoids problems such as uneven heating, clumping, and incomplete drying caused by material accumulation, guaranteeing the drying quality of pharmaceutical materials and preventing the destruction of active ingredients.

This utility model relates to a cleanroom air conditioning and dust removal system, belonging to the field of cleanroom technology in the pharmaceutical industry. The system includes a combined cleanroom air conditioning unit, a bag filter, an air supply duct network, a high-efficiency filter air outlet, a return air duct network, a dust removal exhaust hood, a dust removal static pressure box, a dust concentration sensor, and a controller. The bag filter is rigidly connected to the air conditioning unit side-by-side and fixed to the floor of the equipment room, eliminating interference from the equipment to the cleanroom. The outlet of the bag filter is directly connected to the mixing section of the air conditioning unit through the return air duct network, forcibly reusing the dust-removed air as return air. The dust concentration sensor is embedded in the inner wall of the dust removal static pressure box, directly exposed to the dust-laden airflow channel. This application significantly reduces the air conditioning cooling and heating load by physically reducing the demand for fresh air; the centralized layout of the equipment room frees up space in the cleanroom, improving the convenience of operation and maintenance; and the closed-loop dust collection and multi-stage filtration ensure the stability of cleanliness levels D and above.

This application discloses a method and device for aligning pharmaceutical entity data based on multimodal feature fusion. The method includes: acquiring multi-source data records containing entity name, first identity identifier, second identity identifier, related person information, and address information; constructing a core identity feature tuple composed of the entity name and dual identity identifiers to perform a first-level analysis; when the first-level analysis result is a partial mismatch, performing a second-level analysis based on the consistency of related person information and semantic proximity of addresses to determine whether the records point to the same entity; and merging and updating data determined to be from the same entity based on the date of the valid certificate. This application effectively addresses the unique "separation of licenses and permits" and information inconsistency issues in the pharmaceutical industry, significantly improving the accuracy and automation level of entity data alignment.

The group of inventions relates to the field of medicine, pharmacology and the chemical and pharmaceutical industry and includes an improved method for producing (10S, 13S, 16R, 17R)-17-hydroxy-10,13,16-trimethyl-17-propanoyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthrene-3-one (compound of formula (I)) and the use thereof for industrial batch, semi-continuous and continuous chemical production. Also described is a method for producing an intermediate compound, Vamorolone Acetate. The method for producing the compound of formula (I) is carried out according to the schema depicted. The production method makes it possible to produce the compound of formula (I) with a purity suitable for the use thereof in a finished dosage form for subjects requiring treatment for Duchenne muscular dystrophy. Thus, the technical results of the present invention consist in an improved production method which results in: a high yield and chemical purity, including stereoisomeric purity, of the compound of formula (I) and intermediate products in the synthesis of the compound of formula (I), which are suitable for use in a finished dosage form for subjects requiring treatment for Duchenne muscular dystrophy; the adaptability of the synthesis of the compound of formula (I) to industrial production; environmentally-friendly production; and a decrease in the formation of undesirable by-products.

The present invention discloses a supercritical fluid fluidized continuous extraction and separation system and process, which can be widely used in the fields of chemical industry, food industry, pharmaceutical industry, etc., and has broad prospects. The system consists of a supercritical fluidized continuous extraction system, a pressure reduction separation system, a supercritical working medium refrigeration system, and a supercritical fluid circulation and pressurization system. Among them, the supercritical fluidized continuous extraction system includes a material feeding subsystem, a material fluidized extraction subsystem and an extract residue separation subsystem. The present invention adopts a fluidized extraction process, realizes continuous extraction through a designed supercritical fluid circulation system, and realizes the recycling of supercritical fluid through other supporting equipment and systems, which reduces the failure rate of the device, improves the feeding efficiency, reduces energy consumption, and improves the resource utilization efficiency.

Cleaning-in-place (CIP) systems utilize membrane filters for purifying liquid substances in many industries, including but not limited to, the dairy industry, breweries, pharmaceutical industry, and the food industry. These membrane filters undergo a rigorous cleaning process that despite cleaning can leave foulants on the membranes which hamper filter effectiveness. In addition to the cleaning, enzymes can be applied to the membranes to remove foulants and restore filtering effectiveness. However, introduction of enzymes into these CIP systems can be problematic if enzymes remain after cleaning. This disclosure provides a system and methods to mimic the membrane modules and verify that a correct inactivation procedure occurred. The systems and methods include a separate membrane sample so that no membrane modules need be removed to verify full enzyme inactivation.

The invention relates to the field of pharmaceutical industry, in particular to a pill production packaging machine which comprises a supporting frame, a mounting cylinder, a feeding pipe, a discharging pipe, a rotating cylinder, a supporting rod and the like. The support frame is fixedly connected with a mounting cylinder; the mounting cylinder is communicated with a feeding pipe; the mounting cylinder is communicated with a discharging pipe; the mounting cylinder is rotationally connected with a rotating cylinder; a plurality of supporting rods are slidably connected to the front side and the rear side of the rotary drum, the number of the supporting rods is matched with that of the through grooves, and the supporting rods are distributed in a central symmetry mode. By arranging the rotating cylinder, the supporting rods, the mounting plate, the collecting frame, the rotating assembly, the pushing assembly and the power assembly, when pills rotate in the mounting cylinder, the contact points of the pills are continuously changed under the driving of the two adjacent supporting rods, the broken pills are automatically removed and recycled, and the broken pills are prevented from being mixed into qualified products and flowing into the market.

The utility model relates to low temperature crystallization technical field, and disclose a kind of low temperature crystallization device of convenient energy saving, including base, the top end of base is fixedly connected with base at left side place close, the middle part of base is fixedly sleeved with double-layer heat preservation crystallization jar, the top end of double-layer heat preservation crystallization jar is fixedly connected with protective shell, the top end middle part of base is fixedly connected with support seat, the top end right side of base is fixedly connected with mixing tank, the rear side of double-layer heat preservation crystallization jar is equipped with refrigerant outlet, and then backflow to refrigeration compressor through refrigerant outlet, pass through the flow of multiple-point temperature sensor data adjustment, the accurate cooling crystallization of mixed solution in double-layer heat preservation crystallization jar, open electric valve two, high temperature refrigerant is transferred to the heat preservation layer of mixing tank through high temperature refrigerant pipe, heat exchange is carried out to the medical intermediate mixed solution to be preheated, make medical intermediate mixed solution temperature rise, simultaneously make high temperature refrigerant cool, it is favorable to improve energy utilization, guarantee the development demand of energy saving and cost reduction of pharmaceutical industry.

The application discloses a kind of methyl aspartate lyase EcMAL mutant and its preparation method and application, belong to enzyme engineering technical field.The methyl aspartate lyase EcMAL mutant is any one of mutant EcMAL-M1, mutant EcMAL-M2, mutant EcMAL-M3 and mutant EcMAL-M4.The application is obtained methyl aspartate lyase EcMAL mutant by the mutation of the 329th, 331st, 361st and 365th amino acid sites of methyl aspartate lyase combined with high-throughput screening method.The mutant changes the previous recombinant enzyme only L-aspartic acid production status, so that it is possible to produce D-aspartic acid with methyl aspartate lyase as biological catalyst, and it is expected to be used in pharmaceutical industry.